US › Healthcare

ProPhase Labs Inc (PRPH)

US · Healthcare · Diagnostics & Research

$0.05+15.66%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$478,000

Revenue YoY

-66.6%

Net profit

$-5.4M

Profit YoY

-235.0%

EPS

$0.00

EPS estimate

$-0.12

Net margin

-1,120.1%

EPS came in at 0.00 against a street estimate of -0.12 — a beat of 100.0%.

Key statistics

Market cap

$434,502

Forward P/E

10.5

P/B

0.37

Book value

$-0.04

EPS (TTM)

$-1.85

52-week high

$6.66

52-week low

$0.04

50-day MA

$0.09

200-day MA

$0.75

Beta

0.13

Analyst view

Analysts rate ProPhase Labs Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $13.80.

Shareholding

Insiders

2.37%

Institutions

0.07%

Largest institutional holders

Fund	Stake
Vanguard Group Inc	0.38%
CoreCap Advisors, LLC	0.00%
State Street Corp	0.00%
Susquehanna International Group, LLP	0.00%
BlackRock Inc	0.00%
Jane Street Group LLC	0.00%
Wells Fargo & Co	0.00%
Tower Research Capital LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ProPhase Labs Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.